MCID: LNG035
MIFTS: 54

Lung Large Cell Carcinoma

Categories: Cancer diseases, Neuronal diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Lung Large Cell Carcinoma

MalaCards integrated aliases for Lung Large Cell Carcinoma:

Name: Lung Large Cell Carcinoma 12 15
Large Cell Carcinoma of Lung 12 71
Large Cell Lung Carcinoma 12 17
Large Cell Lung Cancer 54

Classifications:



External Ids:

Disease Ontology 12 DOID:4556
NCIt 49 C4450
UMLS 71 C0345958

Summaries for Lung Large Cell Carcinoma

MalaCards based summary : Lung Large Cell Carcinoma, also known as large cell carcinoma of lung, is related to large cell neuroendocrine carcinoma and pulmonary large cell neuroendocrine carcinoma. An important gene associated with Lung Large Cell Carcinoma is ROS1 (ROS Proto-Oncogene 1, Receptor Tyrosine Kinase), and among its related pathways/superpathways are ERK Signaling and Akt Signaling. The drugs Sirolimus and Everolimus have been mentioned in the context of this disorder. Affiliated tissues include lung, lymph node and breast, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Large-cell carcinoma (LCC) is a heterogeneous group of undifferentiated malignant neoplasms that lack... more...

Related Diseases for Lung Large Cell Carcinoma

Diseases in the Lung Large Cell Carcinoma family:

Small Cell Cancer of the Lung Lung Clear Cell Carcinoma

Diseases related to Lung Large Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 157)
# Related Disease Score Top Affiliating Genes
1 large cell neuroendocrine carcinoma 31.0 SYP NCAM1 CHGA
2 pulmonary large cell neuroendocrine carcinoma 31.0 SYP NCAM1 CHGA
3 adenocarcinoma 30.0 ROS1 NTRK3 FGFR1 EPHA5 EPHA3
4 lung squamous cell carcinoma 29.7 TTN ROS1 MYO18B MTOR FGFR1 EPHA3
5 neuroendocrine carcinoma 28.8 SYP NCAM1 CHGA
6 small cell carcinoma 28.8 SYP NCAM1 CHGA
7 large cell carcinoma 27.6 SYP STK33 ROS1 NTRK3 NCAM1 MTOR
8 lung cancer 11.6
9 lung mixed small cell and squamous cell carcinoma 11.5
10 myeloid and lymphoid neoplasms associated with pdgfra rearrangement 10.5 FGFR1 ABL1
11 lymphoblastic leukemia, acute, with lymphomatous features 10.5 FGFR1 ABL1
12 pectus excavatum 10.2 DDR2 ABL1
13 lymphatic system cancer 10.2 TTN NCAM1 MTOR
14 rosette-forming glioneuronal tumor 10.2 SYP FGFR1
15 spinal cord oligodendroglioma 10.0 SYP FGFR1
16 thrombocytosis 10.0
17 pulmonary tuberculosis 10.0
18 anal neuroendocrine tumor 10.0 SYP NCAM1
19 lung combined type small cell carcinoma 10.0 SYP NCAM1
20 hypoganglionosis 10.0 SYP NCAM1
21 lethal congenital contracture syndrome 10.0
22 vasculitis 10.0
23 squamous cell carcinoma 9.9
24 cerebrofacial arteriovenous metameric syndrome 9.9
25 cerebellopontine angle primitive neuroectodermal 9.9 SYP NCAM1
26 biliary tract benign neoplasm 9.9 SYP NCAM1
27 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 9.8
28 rhabdoid tumor predisposition syndrome 1 9.8
29 pleurisy 9.8
30 pneumothorax 9.8
31 rhabdoid cancer 9.8
32 pleural empyema 9.8
33 lymphoepithelioma-like carcinoma 9.8
34 large cell carcinoma with rhabdoid phenotype 9.8
35 autoimmune disease 9.8
36 retinal detachment 9.8
37 aland island eye disease 9.8
38 reflex sympathetic dystrophy 9.8
39 lung cancer susceptibility 3 9.8
40 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 9.8
41 cutaneous t cell lymphoma 9.8
42 dermatomyositis 9.8
43 respiratory failure 9.8
44 algoneurodystrophy 9.8
45 calcinosis 9.8
46 rectum cancer 9.8
47 rectum adenocarcinoma 9.8
48 inner ear disease 9.8
49 choriocarcinoma 9.8
50 spindle cell carcinoma 9.8

Graphical network of the top 20 diseases related to Lung Large Cell Carcinoma:



Diseases related to Lung Large Cell Carcinoma

Symptoms & Phenotypes for Lung Large Cell Carcinoma

GenomeRNAi Phenotypes related to Lung Large Cell Carcinoma according to GeneCards Suite gene sharing:

26 (show top 50) (show all 63)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 11.32 EPHA3 MTOR
2 Decreased viability GR00173-A 11.32 ANKK1
3 Decreased viability GR00221-A-1 11.32 ABL1 BMX MTOR ROS1 DDR2 FGFR1
4 Decreased viability GR00221-A-2 11.32 ABL1 EPHA5 TTN ROS1 DDR2 FGFR1
5 Decreased viability GR00221-A-3 11.32 ABL1 EPHA5
6 Decreased viability GR00221-A-4 11.32 BMX EPHA5 TTN EPHA3 MTOR DDR2
7 Decreased viability GR00301-A 11.32 EPHA3
8 Decreased viability GR00342-S-1 11.32 ABL1 TTN EPHA3 MTOR ROS1
9 Decreased viability GR00342-S-2 11.32 ABL1 MTOR
10 Decreased viability GR00342-S-3 11.32 ABL1 BMX EPHA5 TTN
11 Decreased viability GR00402-S-2 11.32 ABL1 BMX EPHA5 TTN EPHA3 MTOR
12 Decreased substrate adherent cell growth GR00193-A-1 10.39 ATR BRSK1 ROS1 STK33 TTN
13 Decreased substrate adherent cell growth GR00193-A-2 10.39 ABL1 ROS1 ALPK3 EPHA3 MTOR
14 Decreased substrate adherent cell growth GR00193-A-4 10.39 ABL1 ANKK1 FGFR1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.37 ABL1 DDR2
16 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.37 ABL1 MTOR
17 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.37 DDR2
18 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.37 ATR
19 Increased shRNA abundance (Z-score > 2) GR00366-A-12 10.37 NME1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-123 10.37 ABL1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-13 10.37 NME1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-137 10.37 NTRK3
23 Increased shRNA abundance (Z-score > 2) GR00366-A-138 10.37 BRSK1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.37 ABL1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.37 NTRK3
26 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.37 ABL1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.37 DDR2 MTOR
28 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.37 ATR
29 Increased shRNA abundance (Z-score > 2) GR00366-A-173 10.37 MTOR
30 Increased shRNA abundance (Z-score > 2) GR00366-A-174 10.37 DDR2
31 Increased shRNA abundance (Z-score > 2) GR00366-A-183 10.37 BRSK1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-186 10.37 DDR2
33 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.37 BRSK1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.37 ATR
35 Increased shRNA abundance (Z-score > 2) GR00366-A-2 10.37 ATR
36 Increased shRNA abundance (Z-score > 2) GR00366-A-211 10.37 DDR2
37 Increased shRNA abundance (Z-score > 2) GR00366-A-24 10.37 DDR2
38 Increased shRNA abundance (Z-score > 2) GR00366-A-3 10.37 ABL1
39 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.37 ABL1 NTRK3
40 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.37 DDR2
41 Increased shRNA abundance (Z-score > 2) GR00366-A-4 10.37 BRSK1
42 Increased shRNA abundance (Z-score > 2) GR00366-A-41 10.37 NTRK3
43 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.37 MTOR NTRK3
44 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.37 ABL1
45 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.37 ABL1
46 Increased shRNA abundance (Z-score > 2) GR00366-A-57 10.37 NME1
47 Increased shRNA abundance (Z-score > 2) GR00366-A-60 10.37 MTOR NTRK3
48 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.37 ATR BRSK1
49 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.37 MTOR
50 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.37 DDR2

MGI Mouse Phenotypes related to Lung Large Cell Carcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.11 ABL1 ATR BRSK1 EPHA3 EPHA5 FGFR1
2 mortality/aging MP:0010768 10.1 ABL1 ALPK3 ATR BRSK1 CHGA DDR2
3 cardiovascular system MP:0005385 10.06 ABL1 ALPK3 ATR CHGA DDR2 EPHA3
4 muscle MP:0005369 9.76 ABL1 ALPK3 CHGA DDR2 FGFR1 MTOR
5 nervous system MP:0003631 9.73 ABL1 ATR BRSK1 CHGA DDR2 EPHA5
6 normal MP:0002873 9.28 ABL1 ATR BMX BRSK1 FGFR1 MTOR

Drugs & Therapeutics for Lung Large Cell Carcinoma

Drugs for Lung Large Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 95)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
2
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
3
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
4 Antibiotics, Antitubercular Phase 4
5 Antifungal Agents Phase 4
6
Vindesine Approved, Investigational Phase 3 53643-48-4, 59917-39-4 40839
7
Vinblastine Approved Phase 3 865-21-4 13342 241903
8
Etoposide Approved Phase 3 33419-42-0 36462
9
Bevacizumab Approved, Investigational Phase 3 216974-75-3
10
leucovorin Approved Phase 3 58-05-9 6006 143
11
Pemetrexed Approved, Investigational Phase 3 150399-23-8, 137281-23-3 446556 60843
12
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
13
Celecoxib Approved, Investigational Phase 3 169590-42-5 2662
14
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
15
Lenograstim Approved, Investigational Phase 3 135968-09-1
16
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
17
Tirapazamine Investigational Phase 3 27314-97-2
18 Hematinics Phase 3
19 Topoisomerase Inhibitors Phase 3
20 Etoposide phosphate Phase 3
21 Epoetin alfa Phase 3 113427-24-0
22 Antineoplastic Agents, Immunological Phase 3
23 Antibodies, Monoclonal Phase 3
24 Antibodies Phase 3
25 Immunoglobulins Phase 3
26 Mitogens Phase 3
27 Endothelial Growth Factors Phase 3
28 Immunoglobulin G Phase 3
29 Folic Acid Antagonists Phase 3
30 Vitamin B Complex Phase 3
31 Vitamin B9 Phase 3
32 Folate Phase 3
33 Anti-Bacterial Agents Phase 3
34 Angiogenesis Inhibitors Phase 3
35 Analgesics Phase 3
36 Analgesics, Non-Narcotic Phase 3
37 Anti-Inflammatory Agents, Non-Steroidal Phase 3
38 Cyclooxygenase 2 Inhibitors Phase 3
39 Anti-Inflammatory Agents Phase 3
40 Antirheumatic Agents Phase 3
41 Cyclooxygenase Inhibitors Phase 3
42
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
43
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
44
Lomustine Approved, Investigational Phase 2 13010-47-4 3950
45
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
46
Fluoxetine Approved, Vet_approved Phase 2 54910-89-3 3386
47
Amifostine Approved, Investigational Phase 2 20537-88-6 2141
48
Cobalt Approved, Experimental Phase 2 7440-48-4 104729
49
Romidepsin Approved, Investigational Phase 1, Phase 2 128517-07-7 5352062
50
Darbepoetin alfa Approved, Investigational Phase 2 209810-58-2, 11096-26-7

Interventional clinical trials:

(show top 50) (show all 125)
# Name Status NCT ID Phase Drugs
1 A Multi-centric, Open-label, Phase II Study Investigating the Combination of Afinitor With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced (Stage IV) Large Cell Lung Cancer With Neuroendocrine Differentiation (LC-NEC) Completed NCT01317615 Phase 4 RAD001;Paclitaxel;Carboplatin
2 A Randomized, Phase III Trial of Prophylactic Cranial Irradiation (PCI) in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Are Nonprogressive on Gefitinib or Erlotinib Unknown status NCT00955695 Phase 3 erlotinib hydrochloride;gefitinib
3 A Prospective Study of the Prognostic Significance of Occult Metastases in the Patient With Resectable Non-Small Cell Lung Carcinoma Completed NCT00003901 Phase 3
4 Phase III Randomized Comparison Study of Vinorelbine, Gemcitabine, and Docetaxel Versus Paclitaxel and Carboplatin in Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00079287 Phase 3 carboplatin;docetaxel;gemcitabine hydrochloride;paclitaxel;vinorelbine tartrate
5 Randomized Trial of Mediastinal Lymph Node Sampling Versus Complete Lymphadenectomy During Pulmonary Resection in the Patient With N0 and N1 (Less Than Hilar) Non-Small Cell Carcinoma Completed NCT00003831 Phase 3
6 A Phase III Trial of Single Versus Fractionated Thoracic Radiation for Palliation of Symptoms in Patients With Non-Small Cell Lung Cancer Completed NCT00003685 Phase 3
7 Single-Agent Versus Combination Chemotherapy in Advanced NSCLC: A CALGB Randomized Trial of Efficacy, Quality of Life, and Cost-Effectiveness Completed NCT00003117 Phase 3 carboplatin;paclitaxel
8 Randomized Phase III Trial Of Carboplatin And Paclitaxel Plus Tirapazamine Versus Carboplatin And Paclitaxel In Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00006484 Phase 3 carboplatin;paclitaxel;tirapazamine
9 Concurrent Carboplatin, Paclitaxel, and Radiation Therapy Versus Induction Carboplatin and Paclitaxel Followed by Concurrent Carboplatin, Paclitaxel and Radiation Therapy for Patients With Unresectable Stage III Non-Small Cell Lung Cancer: A Phase III Trial Completed NCT00003387 Phase 3 carboplatin;chemotherapy;paclitaxel
10 A Phase III Trial of Induction Paclitaxel and Carboplatin Followed By Standard Radiotherapy (64 Gy/7 Weeks) vs. Hyperfractionated Accelerated Radiotherapy (HART 57.6 Gy/2.5 Weeks) For Patients With Unresectable Stage IIIA and IIIB Non-Small Cell Lung Cancer Completed NCT00003235 Phase 3 carboplatin;paclitaxel
11 A LARGE-SCALE TRIAL EVALUATING ADJUVANT CHEMOTHERAPY AFTER CURATIVE RESECTION OF NON-SMALL CELL LUNG CANCER Completed NCT00002823 Phase 3 cisplatin;etoposide;vinblastine sulfate;vindesine;vinorelbine tartrate
12 A Phase III Randomized Trial Evaluating the Effect of Epoetin Alfa (Procrit) on Local Control in Patients Undergoing Concurrent Chemotherapy and Radiation Therapy for Non-Small Cell Lung Cancer Completed NCT00028938 Phase 3 carboplatin;paclitaxel
13 RANDOMIZED TRIAL OF SURGERY VERSUS RADIOTHERAPY IN PATIENTS WITH STAGE IIIa NON-SMALL CELL LUNG CANCER AFTER A RESPONSE TO INDUCTION-CHEMOTHERAPY Completed NCT00002623 Phase 3 carboplatin;cisplatin
14 A Phase III Comparison Between Concurrent Chemotherapy Plus Radiotherapy and Concurrent Chemotherapy Plus Radiotherapy Followed by Surgical Resection for Stage IIIA (N2) Non-Small Cell Lung Cancer Completed NCT00002550 Phase 3 cisplatin;etoposide
15 A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer Active, not recruiting NCT00499330 Phase 3
16 Preoperative Chemoradiotherapy vs. Chemotherapy Alone in Non-small Cell Lung Cancer (NSCLC) Patients With Mediastinal Lymph Node Metastases (Stage IIIA, N2): A Randomized Prospective Phase III Trial Active, not recruiting NCT00030771 Phase 3 Chemotherapy
17 A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab With or Without Concurrent Cetuximab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Active, not recruiting NCT00946712 Phase 3 Carboplatin;Paclitaxel
18 Randomized Phase III Study of Maintenance Therapy With Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC Active, not recruiting NCT01107626 Phase 3 pemetrexed disodium
19 A Randomized Phase III Trial of Adjuvant Chemotherapy in Patients With Early Stage Non-Small Cell Lung Cancer Associated With Banking of Frozen Tumor Specimens and Collection of Gene Expression Profile Data Terminated NCT00863512 Phase 3 cisplatin;docetaxel;gemcitabine hydrochloride;pemetrexed disodium;vinorelbine tartrate
20 A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer Terminated NCT01041781 Phase 3 carboplatin;celecoxib;gemcitabine hydrochloride;pemetrexed disodium
21 Double Blind Randomized Phase III Study of Maintenance Pazopanib Versus Placebo in NSCLC Patients Non Progressive After First Line Chemotherapy. MAPPING, an EORTC Lung Group Study. Terminated NCT01208064 Phase 2, Phase 3 pazopanib hydrochloride
22 Phase III Randomized Trial of Preoperative Chemotherapy Versus Preoperative Concurrent Chemotherapy and Thoracic Radiotherapy Followed by Surgical Resection and Consolidation Chemotherapy in Favorable Prognosis Patients With Stage IIIA (N2) Non-Small Cell Lung Cancer Terminated NCT00113386 Phase 3 cisplatin;docetaxel
23 A Randomized Phase III Trial of Carboplatin, Paclitaxel and Thoracic Radiotherapy, With or Without Thalidomide, in Patients With Stage III Non-Small Cell Lung Cancer (NSCLC) Terminated NCT00004859 Phase 3 carboplatin;paclitaxel;thalidomide
24 A Randomized, Phase III Multicenter Trial Of Gemcitabine In Combination With Carboplatin Or Paclitaxel Plus Carboplatin In Patients With Metastatic (Stage IIIB, IV) Non-Small Cell Lung Cancer Withdrawn NCT00054392 Phase 3 carboplatin;gemcitabine hydrochloride;paclitaxel
25 A Phase III Randomized, Open-Label Comparative Study of Induction Chemotherapy Followed by Thoracic Radiation Therapy With Supplemental Oxygen, With or Without Concurrent RSR13 (Efaproxiral), in Patients With Locally Advanced Unresectable (Stage IIIA/IIIB) Non-Small Cell Lung Cancer Withdrawn NCT00055887 Phase 3 carboplatin;cisplatin;efaproxiral;gemcitabine hydrochloride;paclitaxel;vinorelbine ditartrate
26 A Phase II Study of Non-Small Cell Cancer of the Lung Utilizing Low-Dose Weekly Therapy of Taxotere and Carboplatin Unknown status NCT00003562 Phase 2 carboplatin;docetaxel
27 Phase II Study Of Gemcitabine And Docetaxel In Patients With Inoperable Stage IIIB Or IIIB or IV Non-Small Cell Lung Cancer Unknown status NCT00075517 Phase 2 docetaxel;gemcitabine hydrochloride
28 A Phase II Multicenter Study Of Lometrexol Sodium And Folic Acid In Subjects With Previously Treated Stage IIIB or IV Non-Small Cell Lung Cancer Unknown status NCT00033722 Phase 2 lometrexol
29 First Line Treatment of Stage IIIb/IV Non Small Cell (NSC) Lung Cancer With a Bimonthly Administration of a Combination of Cisplatin-Gemcitabine Unknown status NCT00006116 Phase 2 cisplatin;gemcitabine hydrochloride
30 Phase II Trial Assessing the Impact on Instrumental and Daily Living Autonomy of a Chemotherapy Regimen With Bi-Weekly Docetaxel in the Treatment of Metastatic or Locally Advanced Non-Small Cell Lung Cancer in Patients Over the Age of 70 Unknown status NCT00227708 Phase 2 docetaxel
31 A Phase II Trial of Neoadjuvant Gefitinib Therapy Based on Mutation Study in Biopsy- Proven Stage IIIA N2 Non-Squamous Non-Small Cell Lung Cancer Unknown status NCT00616499 Phase 2 gefitinib
32 Paclitaxel/Carboplatin Combined With Intermittent Gefitinib in Patients With Untreated Advanced Non-small Cell Lung Cancer: A Phase Ⅱa Trial Unknown status NCT01024712 Phase 2 carboplatin;gefitinib;paclitaxel
33 A Randomized Phase II Study of Preoperative Versus Postoperative Gemcitabine and Cisplatin for Patients With Stage IB-II Non-Small Cell Lung Cancer Unknown status NCT00398385 Phase 2 cisplatin;gemcitabine hydrochloride
34 A Phase Ib, Open-label Study to Evaluate RAD001 as Monotherapy Treatment in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor Unknown status NCT01175096 Phase 1, Phase 2 RAD001 (everolimus, Afinitor®)
35 Phase II Study Of TLK286 For The Treatment Of Advanced Non-Small Cell Lung Cancer Completed NCT00036920 Phase 2 canfosfamide hydrochloride
36 A Phase II Study Of Temozolomide In The Treatment Of Patients With Metastatic Non-Small Cell Lung Cancer Completed NCT00006877 Phase 2 temozolomide
37 Preoperative Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Patients With Mediastinal Lymph Node Metastases (Stage IIIA, N2) Completed NCT00003231 Phase 2 cisplatin;docetaxel
38 Vinorelbine Plus Bevacizumab as First Line Therapy in Patients ≥ 70 Years of Age With Stage IIIB/IV Non-Squamous, Non-Small Cell Lung Cancer Completed NCT00309998 Phase 2 vinorelbine tartrate
39 A Phase II Study of Taxotere and Gemcitabine for Stages III-B and IV Non-Small Cell Lung Cancer Completed NCT00278460 Phase 2 docetaxel;gemcitabine hydrochloride
40 Phase II Trial of Gemcitabine/Paraplatin® (Carboplatin) Followed by Taxol® (Paclitaxel) in Patients With Performance Status = 2,3 or Other Significant Co-Morbidity (HIV Infection or s/p Organ Transplantation) in Advanced Non-Small Cell Lung Cancer Completed NCT00276588 Phase 2 carboplatin;gemcitabine hydrochloride;paclitaxel
41 Preoperative Chemoradiotherapy In Non-Small Cell Lung Cancer (NSCLC) Patients With Operable Stage IIIB Disease: A Prospective Phase II Trial Completed NCT00030810 Phase 2 Taxotere/Cisplatin
42 Phase II Study of Carboplatin, Irinotecan, and Thalidomide in Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00025285 Phase 2 carboplatin;irinotecan hydrochloride;thalidomide
43 Phase II Trial Of Karenitecin (IND 57250) In Patients With Relapsed or Refractory Non-small Cell Lung Cancer Completed NCT00010218 Phase 2 karenitecin
44 A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Patients With Medically Inoperable Stage I/II Non-Small Cell Lung Cancer Completed NCT00087438 Phase 2
45 Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer Completed NCT00003666 Phase 2 6-hydroxymethylacylfulvene
46 VIDEO ASSISTED WEDGE RESECTION (VAR) AND RADIOTHERAPY FOR HIGH RISK T1 NON-SMALL CELL LUNG CANCER: A PHASE II STUDY Completed NCT00002624 Phase 2
47 Phase II Study of CCNU (Lomustine) in Patients With Advanced Non-Small Cell Lung Cancer and Aberrant Hypermethylation of the MGMT Gene Completed NCT00293280 Phase 2 lomustine
48 A Phase II Study of Accelerated Hypofractionated 3-Dimensional Conformal Radiotherapy (3DCRT) For Inoperable Stage I/II Non-Small Cell Lung Cancer (NSCLC) Completed NCT00346320 Phase 2
49 A Phase II Study of Induction Chemotherapy Followed by Thoracic Radiotherapy and Erlotinib in Poor-Risk Stage III Non-Small Cell Lung Cancer Completed NCT00553462 Phase 2 carboplatin;erlotinib hydrochloride;paclitaxel albumin-stabilized nanoparticle formulation
50 A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Patients With Operable Stage I/II Non-Small Cell Lung Cancer Completed NCT00551369 Phase 2

Search NIH Clinical Center for Lung Large Cell Carcinoma

Genetic Tests for Lung Large Cell Carcinoma

Anatomical Context for Lung Large Cell Carcinoma

MalaCards organs/tissues related to Lung Large Cell Carcinoma:

40
Lung, Lymph Node, Breast, Brain, Prostate, Endothelial, Thyroid

Publications for Lung Large Cell Carcinoma

Articles related to Lung Large Cell Carcinoma:

(show top 50) (show all 220)
# Title Authors PMID Year
1
Cancer-associated Retinopathy with Neuroendocrine Combined Large-cell Lung Carcinoma and Adenocarcinoma. 61
31327819 2019
2
Inhibition of bone morphogenetic protein signaling reduces viability, growth and migratory potential of non-small cell lung carcinoma cells. 61
31531741 2019
3
Unraveling the large cell lung carcinoma-specific miRNA profile and the downstream regulation network. 61
31555828 2019
4
Klotho expression and nodal involvement as predictive factors for large cell lung carcinoma. 61
31360195 2019
5
Doxycycline inhibits electric field-induced migration of non-small cell lung cancer (NSCLC) cells. 61
31147570 2019
6
Outcomes comparison between neoadjuvant chemotherapy and adjuvant chemotherapy in stage IIIA non-small cell lung cancer patients. 61
31179087 2019
7
Connexin43 Suppresses Lung Cancer Stem Cells. 61
30717421 2019
8
Integrative gene expression profiling reveals that dysregulated triple microRNAs confer paclitaxel resistance in non-small cell lung cancer via co-targeting MAPT. 61
31496800 2019
9
Clinical characteristics and prognosis of basaloid squamous cell carcinoma of the lung: a population-based analysis. 61
31106047 2019
10
Gefitinib in the Treatment of a Pulmonary Sequestration Patient Complicated by Large Cell Lung Carcinoma. 61
30166013 2018
11
Metachronous gastric metastasis from lung primary, with synchronous pancreatic neuroendocrine carcinoma. 61
29988660 2018
12
Anticancer Gold(III) Peptidomimetics: From Synthesis to in vitro and ex vivo Biological Evaluations. 61
29570944 2018
13
Clinicopathological analysis of Large Cell Lung Carcinomas definitely diagnosed according to the New World Health Organization Criteria. 61
29525405 2018
14
Stereochemical Structure Activity Relationship Studies (S-SAR) of Tetrahydrolipstatin. 61
29541373 2018
15
The investigation of ceranib-2 on apoptosis and drug interaction with carboplatin in human non small cell lung cancer cells in vitro. 61
29230631 2018
16
Unravelling the Long Non-Coding RNA Profile of Undifferentiated Large Cell Lung Carcinoma. 61
29657301 2018
17
Epigenetic Regulation of EMT in Non-Small Cell Lung Cancer. 61
28176646 2018
18
Personalized siRNA-Nanoparticle Systemic Therapy using Metastatic Lymph Node Specimens Obtained with EBUS-TBNA in Lung Cancer. 61
28993508 2018
19
Laparoscopic Splenectomy for Splenic Metastasis from Primary Lung Carcinoma. 61
29732229 2018
20
Correlation between STK33 and the pathology and prognosis of lung cancer. 61
29085482 2017
21
TRIM59 is a novel potential prognostic biomarker in patients with non-small cell lung cancer: A research based on bioinformatics analysis. 61
28789440 2017
22
[Clinicopathologic features and genetic profile of the redefined large cell lung carcinoma]. 61
28468033 2017
23
Comparison of human lung cancer cell radiosensitivity after irradiations with therapeutic protons and carbon ions. 61
27633574 2017
24
[Precision medical treatment of non-adenocarcinoma NSCLC patients with EGFR mutation]. 61
28219201 2017
25
A global view of regulatory networks in lung cancer: An approach to understand homogeneity and heterogeneity. 61
27894849 2017
26
Clinical efficacy evaluation of tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations. 61
28790845 2017
27
Immune-associated proteins with potential in vivo anti-tumor activities are upregulated in lung cancer cells treated with umbelliprenin: A proteomic approach. 61
28105238 2016
28
[Two Cases of Small Intestinal Metastasis of Lung Cancer]. 61
28133150 2016
29
Differentiating brain metastases from different pathological types of lung cancers using texture analysis of T1 postcontrast MR. 61
26621795 2016
30
Variations of chromosome 2 gene expressions among patients with lung cancer or non-cancer. 61
27301951 2016
31
Discovery of 'click' 1,2,3-triazolium salts as potential anticancer drugs. 61
27679544 2016
32
Blood-borne miRNA profile-based diagnostic classifier for lung adenocarcinoma. 61
27507195 2016
33
Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations in China. 61
26942444 2016
34
Treatment of lung large cell neuroendocrine carcinoma. 61
26943800 2016
35
Four Cu(ii) complexes based on antitumor chelators: synthesis, structure, DNA binding/damage, HSA interaction and enhanced cytotoxicity. 61
27071545 2016
36
[Large-cell lung carcinoma by the 2015 WHO classification: a clinicopathologic analysis of 93 cases]. 61
27033385 2016
37
Brachial metastatic plexopathy as the inaugural manifestation of lung cancer: multimodality imaging. 61
30460024 2016
38
[A clinical review of 3 cases of children with bronchial tumor]. 61
26696483 2015
39
Digging Deep for New Compounds from the Compass Plant, Silphium laciniatum. 61
26287548 2015
40
Large cell lung carcinoma with rhabdoid phenotype: Report of a rare entity presenting with chest wall involvement. 61
26458655 2015
41
Lung transthoracic ultrasound elastography imaging and guided biopsies of subpleural cancer: a preliminary report. 61
24951615 2015
42
Respiratory-gated imaging in metabolic evaluation of small solitary pulmonary nodules: 18F-FDG PET/CT and correlation with histology. 61
25793929 2015
43
Mediastinal small cell cancer associated with Lambert-Eaton myasthenic syndrome: A case report. 61
26170921 2015
44
Global analysis of chromosome 1 genes among patients with lung adenocarcinoma, squamous carcinoma, large-cell carcinoma, small-cell carcinoma, or non-cancer. 61
25937073 2015
45
Oxidative stress associates with aggressiveness in lung large-cell carcinoma. 61
25638031 2015
46
Association of structural modifications with bioactivity in three new copper(II) complexes of Schiff base ligands derived from 5-chlorosalicylaldehyde and amino acids. 61
25771239 2015
47
Accuracy of classifying poorly differentiated non-small cell lung carcinoma biopsies with commonly used lung carcinoma markers. 61
25776027 2015
48
A retrospective analysis of the clinicopathological characteristics of large cell carcinoma of the lung. 61
25452802 2015
49
Bilateral diffuse uveal melanocytic proliferation with good clinical response to plasmapheresis and treatment of the primary tumor. 61
25383840 2015
50
Isolation and characterization of a new cytotoxic dihydrophenanthrene from Dioscorea membranacea rhizomes and its activity against five human cancer cell lines. 61
25149021 2014

Variations for Lung Large Cell Carcinoma

Cosmic variations for Lung Large Cell Carcinoma:

9 (show top 50) (show all 2927)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM149314749 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.1144G>T p.G382C 16:72959002-72959002 18
2 COSM149318860 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.1172A>G p.Q391R 16:72958974-72958974 18
3 COSM143041512 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1316C>T p.P439L 11:102229729-102229729 18
4 COSM97230831 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1159A>C p.I387L 22:41653558-41653558 18
5 COSM85312404 XRCC1 lung,NS,carcinoma,undifferentiated carcinoma c.1207A>G p.M403V 19:43546970-43546970 18
6 COSM91372655 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 18
7 COSM91383011 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1360A>T p.K454* 11:32392044-32392044 18
8 COSM124478343 WNT8A lung,NS,carcinoma,undifferentiated carcinoma c.422G>C p.G141A 5:138088927-138088927 18
9 COSM87652733 WNT10B lung,NS,carcinoma,undifferentiated carcinoma c.1006A>C p.K336Q 12:48966259-48966259 18
10 COSM89575026 WNK3 lung,NS,carcinoma,large cell carcinoma c.4599G>T p.L1533F 23:54236967-54236967 18
11 COSM84601598 USP5 lung,NS,carcinoma,undifferentiated carcinoma c.755C>T p.T252I 12:6856877-6856877 18
12 COSM88410243 USP38 lung,NS,carcinoma,undifferentiated carcinoma c.994G>C p.A332P 4:143197868-143197868 18
13 COSM87541563 USP32 lung,NS,carcinoma,undifferentiated carcinoma c.192T>A p.I64= 17:60301699-60301699 18
14 COSM145430147 UHRF1 lung,NS,carcinoma,undifferentiated carcinoma c.1467C>G p.F489L 19:4947122-4947122 18
15 COSM127070824 UBR5 lung,NS,carcinoma,undifferentiated carcinoma c.2691A>T p.Q897H 8:102305221-102305221 18
16 COSM127059821 UBR5 lung,NS,carcinoma,undifferentiated carcinoma c.1555A>G p.S519G 8:102326590-102326590 18
17 COSM85195038 U2AF1 lung,NS,carcinoma,undifferentiated carcinoma c.319G>C p.D107H 21:43095467-43095467 18
18 COSM130300868 TYK2 lung,NS,carcinoma,undifferentiated carcinoma c.3560G>T p.C1187F 19:10350838-10350838 18
19 COSM140806401 TTN lung,NS,carcinoma,large cell carcinoma c.62102T>A p.L20701Q 2:178589623-178589623 18
20 COSM140594116 TTN lung,NS,carcinoma,large cell carcinoma c.73050T>C p.D24350= 2:178573082-178573082 18
21 COSM140594104 TTN lung,NS,carcinoma,large cell carcinoma c.101435C>A p.T33812N 2:178535180-178535180 18
22 COSM140594111 TTN lung,NS,carcinoma,large cell carcinoma c.73137C>G p.L24379= 2:178572995-178572995 18
23 COSM85297370 TTBK1 lung,NS,carcinoma,large cell carcinoma c.2417C>T p.S806F 6:43283157-43283157 18
24 COSM131090496 TSHR lung,NS,carcinoma,undifferentiated carcinoma c.1922C>T p.S641L 14:81143980-81143980 18
25 COSM131094722 TSHR lung,NS,carcinoma,undifferentiated carcinoma c.412C>T p.L138F 14:81091088-81091088 18
26 COSM131094002 TSHR lung,NS,carcinoma,undifferentiated carcinoma c.937A>C p.K313Q 14:81142995-81142995 18
27 COSM87049256 TSC2 lung,NS,carcinoma,undifferentiated carcinoma c.1840G>T p.A614S 16:2071510-2071510 18
28 COSM85721789 TSC1 lung,NS,carcinoma,undifferentiated carcinoma c.694G>T p.E232* 9:132921406-132921406 18
29 COSM94305492 TRRAP lung,NS,carcinoma,large cell carcinoma c.8069C>T p.P2690L 7:98976613-98976613 18
30 COSM97140529 TRPM6 lung,NS,carcinoma,large cell carcinoma c.3021G>C p.W1007C 9:74782752-74782752 18
31 COSM91855448 TRIB1 lung,NS,carcinoma,large cell carcinoma c.1113C>G p.F371L 8:125436465-125436465 18
32 COSM90140992 TRAF7 lung,NS,carcinoma,undifferentiated carcinoma c.1193C>T p.P398L 16:2173978-2173978 18
33 COSM90145840 TRAF7 lung,NS,carcinoma,undifferentiated carcinoma c.1287C>G p.Y429* 16:2174274-2174274 18
34 COSM87090089 TRAF5 lung,NS,carcinoma,undifferentiated carcinoma c.302G>C p.R101T 1:211356392-211356392 18
35 COSM87898991 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.535C>T p.H179Y 17:7675077-7675077 18
36 COSM87897745 TP53 lung,NS,carcinoma,large cell carcinoma c.524G>A p.R175H 17:7675088-7675088 18
37 COSM87901497 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.461G>T p.G154V 17:7675151-7675151 18
38 COSM87906616 TP53 lung,NS,carcinoma,large cell carcinoma c.725G>T p.C242F 17:7674238-7674238 18
39 COSM87935416 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.499C>T p.Q167* 17:7675113-7675113 18
40 COSM87897711 TP53 lung,NS,carcinoma,large cell carcinoma c.818G>A p.R273H 17:7673802-7673802 18
41 COSM87897832 TP53 lung,NS,carcinoma,large cell carcinoma c.725G>A p.C242Y 17:7674238-7674238 18
42 COSM87924356 TP53 lung,NS,carcinoma,large cell carcinoma c.589G>A p.V197M 17:7674942-7674942 18
43 COSM87904420 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.514G>T p.V172F 17:7675098-7675098 18
44 COSM87897883 TP53 lung,NS,carcinoma,large cell carcinoma c.659A>G p.Y220C 17:7674872-7674872 18
45 COSM87898444 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.536A>G p.H179R 17:7675076-7675076 18
46 COSM87900157 TP53 lung,NS,carcinoma,large cell carcinoma c.818G>T p.R273L 17:7673802-7673802 18
47 COSM87991360 TP53 lung,NS,carcinoma,large cell carcinoma c.714T>A p.C238* 17:7674249-7674249 18
48 COSM87901016 TP53 lung,NS,carcinoma,large cell carcinoma c.734G>T p.G245V 17:7674229-7674229 18
49 COSM87898723 TP53 lung,NS,carcinoma,large cell carcinoma c.817C>T p.R273C 17:7673803-7673803 18
50 COSM87906107 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.473G>T p.R158L 17:7675139-7675139 18

Expression for Lung Large Cell Carcinoma

Search GEO for disease gene expression data for Lung Large Cell Carcinoma.

Pathways for Lung Large Cell Carcinoma

Pathways related to Lung Large Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.57 ROS1 NTRK3 MYO18B MTOR FGFR1 EPHA5
2
Show member pathways
13.18 ROS1 NTRK3 MTOR FGFR1 EPHA5 EPHA3
3
Show member pathways
12.82 NTRK3 MTOR FGFR1 EPHA5 EPHA3 DDR2
4
Show member pathways
12.53 ROS1 NTRK3 MYO18B FGFR1 EPHA5 EPHA3
5
Show member pathways
12.23 NTRK3 MTOR FGFR1 ATR
6
Show member pathways
11.8 ROS1 NTRK3 MTOR FGFR1 EPHA5 EPHA3
7 11.63 NTRK3 EPHA5 EPHA3 ABL1
8 11.57 SYP NCAM1 FGFR1
9 11.49 NTRK3 MTOR FGFR1
10 11.46 NTRK3 FGFR1 EPHA5 EPHA3 BMX
11 11.34 ROS1 FGFR1 EPHA5 EPHA3 DDR2 BMX
12 10.7 ROS1 NTRK3 FGFR1 EPHA5 EPHA3 DDR2

GO Terms for Lung Large Cell Carcinoma

Cellular components related to Lung Large Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 perinuclear region of cytoplasm GO:0048471 9.5 SYP STK33 ROS1 NME1 EPHA5 CHGA
2 receptor complex GO:0043235 9.1 ROS1 NTRK3 FGFR1 EPHA5 EPHA3 DDR2

Biological processes related to Lung Large Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 peptidyl-tyrosine phosphorylation GO:0018108 9.81 TTN ROS1 NTRK3 FGFR1 EPHA5 EPHA3
2 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.8 ROS1 NTRK3 FGFR1 EPHA5 EPHA3 DDR2
3 protein autophosphorylation GO:0046777 9.8 STK33 MTOR FGFR1 DDR2 BMX ATR
4 protein phosphorylation GO:0006468 9.8 TTN STK33 ROS1 NTRK3 MTOR FGFR1
5 positive regulation of neuron projection development GO:0010976 9.77 NTRK3 NME1 MTOR FGFR1 EPHA3
6 regulation of actin cytoskeleton organization GO:0032956 9.71 MTOR EPHA5 EPHA3 ABL1
7 regulation of GTPase activity GO:0043087 9.7 MTOR EPHA5 EPHA3
8 ephrin receptor signaling pathway GO:0048013 9.65 NTRK3 EPHA5 EPHA3
9 regulation of protein kinase B signaling GO:0051896 9.55 NTRK3 MTOR
10 positive regulation of phospholipase C activity GO:0010863 9.54 NTRK3 FGFR1
11 phosphorylation GO:0016310 9.53 TTN STK33 ROS1 NTRK3 NME1 MTOR
12 cardiac muscle fiber development GO:0048739 9.51 TTN MYO18B
13 signal transduction in response to DNA damage GO:0042770 9.49 STK33 ABL1
14 cardiac muscle cell development GO:0055013 9.46 MTOR ALPK3
15 regulation of phosphate transport GO:0010966 9.43 ROS1 FGFR1

Molecular functions related to Lung Large Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 transferase activity GO:0016740 10.22 TTN STK33 ROS1 NTRK3 NME1 MTOR
2 protein kinase activity GO:0004672 10 TTN STK33 ROS1 NTRK3 MTOR FGFR1
3 protein serine/threonine kinase activity GO:0004674 9.95 TTN STK33 MTOR BRSK1 ATR ANKK1
4 protein tyrosine kinase activity GO:0004713 9.91 TTN ROS1 NTRK3 FGFR1 EPHA5 EPHA3
5 kinase activity GO:0016301 9.86 TTN STK33 ROS1 NTRK3 NME1 MTOR
6 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.85 ROS1 NTRK3 FGFR1 EPHA5 EPHA3 DDR2
7 SH2 domain binding GO:0042169 9.63 SYP FGFR1 ABL1
8 GPI-linked ephrin receptor activity GO:0005004 9.61 NTRK3 EPHA5 EPHA3
9 ATP binding GO:0005524 9.55 TTN STK33 ROS1 NTRK3 NME1 MYO18B
10 transmembrane-ephrin receptor activity GO:0005005 9.49 EPHA5 EPHA3
11 ephrin receptor activity GO:0005003 9.48 EPHA5 EPHA3

Sources for Lung Large Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....